Product Information:

APIXAGET 2.5mg Tablets contain Apixaban as the active ingredient, a direct oral anticoagulant (DOAC) that selectively inhibits Factor Xa in the coagulation cascade. This action reduces thrombin generation and prevents the formation of harmful blood clots. APIXAGET is used to lower the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation, and for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Uses of (APIXAGET 2.5MG TABLETS):

APIXAGET 2.5mg Tablets are indicated for:

1. Stroke prevention in adult patients with non-valvular atrial fibrillation and ≥2 additional risk factors (e.g., prior stroke, age ≥75, diabetes, heart failure).
2. Treatment of DVT and PE.
3. Prevention of recurrent DVT and PE in adults who have completed initial therapy.
4. Prophylaxis of venous thromboembolism (VTE) following hip or knee replacement surgery (in specific dosing regimens).

Key Benefits of (APIXAGET 2.5MG TABLETS):

1. No routine coagulation monitoring required
2. Lower risk of major bleeding compared to warfarin
3. Fixed-dose regimen without dietary restrictions
4. Rapid onset of action (within 1–4 hours)
5. Proven efficacy in reducing stroke and systemic embolism

How To Use (APIXAGET 2.5MG TABLETS):

Take one tablet twice daily (approximately 12 hours apart), with or without food. Swallow whole with water—do not crush or chew. Take at the same times each day to maintain consistent anticoagulant effect. Do not stop without consulting your doctor, as abrupt discontinuation increases clotting risk.

When Not to Use (APIXAGET 2.5MG TABLETS):

Do not use if you have active pathological bleeding, severe hepatic impairment, or hypersensitivity to apixaban. Avoid in patients with prosthetic heart valves or antiphospholipid syndrome (APS), as safety and efficacy are not established. Contraindicated in combination with strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, ritonavir).

Side Effects of (APIXAGET 2.5MG TABLETS):

Common: Bleeding (e.g., nosebleeds, bruising, gum bleeding), nausea, anemia.

Serious: Major or life-threatening bleeding (e.g., intracranial, gastrointestinal), spinal/epidural hematoma (especially with neuraxial anesthesia), allergic reactions. Seek emergency care for signs of severe bleeding (unusual weakness, dizziness, pink/brown urine, black/tarry stools).

Dosage: (APIXAGET 2.5MG TABLETS):

The 2.5mg twice-daily dose is specifically used in patients with:

1. Non-valvular AF and ≥2 of: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL.
2. For VTE treatment/prevention in select high-bleeding-risk patients per physician judgment.
3. Always confirm indication-specific dosing with your healthcare provider.

Who It’s For (APIXAGET 2.5MG TABLETS):

Adults with non-valvular atrial fibrillation at increased stroke risk, or those requiring secondary prevention of DVT/PE under medical supervision. Not for use in children, pregnant women (unless clearly needed), or patients with mechanical heart valves.

Warnings & Precautions:

Bleeding risk increases with concomitant NSAIDs, antiplatelets, or other anticoagulants. Discontinue 24–48 hours before invasive procedures if possible. Avoid in patients with CrCl <15 mL/min. Inform all healthcare providers (including dentists) that you are taking APIXAGET. Carry an anticoagulant alert card.

Drug Interactions:

Strong interactions with CYP3A4/P-gp inhibitors (e.g., ketoconazole, clarithromycin) → increased bleeding risk. Inducers (e.g., rifampin, carbamazepine) → reduced efficacy. Concurrent use with aspirin, clopidogrel, or SSRIs also raises bleeding risk. Always review medications with your doctor or pharmacist.

Additional Information:

Store below 30°C in a dry place, away from moisture and light. Keep out of reach of children. Do not use after the expiration date on the blister pack. Available by prescription only in Pakistan.